We are thrilled to announce a groundbreaking collaboration between OBiO Technology (Shanghai) Co., Ltd. ("OBiO Technology", stock code: 688238) and Shanghai Novabio Therapeutics ("Novabio"). On March 22, 2024, both entities formally inked a strategic cooperation agreement that promises to reshape the landscape of Treg cell therapy.
Under this visionary pact, OBiO Technology commits to providing cutting-edge non-registered clinical trial sample preparation and testing services for Novabio's Treg cell therapy pipeline NP001. Moreover, OBiO Technology will extend its expertise to offer IND application CMC services and clinical sample production services for NP001 and NC001 projects. Together, we aspire to deliver tangible benefits to patients, fostering a brighter future for all.
Novabio stands at the forefront of Treg cell therapy drug development, addressing critical gaps in the treatment of neurodegenerative diseases, autoimmune diseases, and metabolic disorders. In a mere year and a half since its inception, Novabio has achieved significant milestones, culminating in the successful process development and validation of the NP001 project. With a primary focus on amyotrophic lateral sclerosis (ALS), plans are underway to conduct innovative IIT research in China, aligning with stringent IND application criteria in both China and the United States.
Meanwhile, OBiO Technology specializes in offering comprehensive CDMO services tailored to gene and cell therapy drug developers. From pre-clinical research to commercial-scale production, OBiO Technology empowers the entire lifecycle of gene and cell therapy drug development. Boasting state-of-the-art facilities, including 15 vector production lines, 20 cell production lines, and integrated lyophilization and filling capabilities, OBiO Technology epitomizes innovation and excellence in the industry. Our commitment to quality extends to advanced experimental equipment, diverse analysis technologies, and robust detection platforms, ensuring the delivery of high-quality products and services to our valued clientele.
Ms.Ya, You, General Manager of Novabio, expressed her elation at the strategic collaboration, citing OBiO Technology's unwavering support in various aspects, including cost management, technological expertise, and scheduling precision. Looking ahead, Novabio envisions an era of expanded collaboration, both domestically and internationally, underpinned by mutual trust, support, and empowerment.
Mr. Javier Jia, CEO and General Manager of OBiO Technology, echoed this sentiment, heralding the partnership with Novabio as a pivotal moment in advancing Treg cell therapy to clinical fruition. As a leading CRO/CDMO enterprise, OBiO Technology remains steadfast in its commitment to driving progress in the global gene and cell therapy field, continuously elevating industry standards through efficient and high-quality service offerings.
Founded in 2022, Shanghai Novabio Therapeutics pioneers multimodal Treg cell therapy for treating neurodegenerative diseases, autoimmune disorders, and metabolic conditions. Anchored by a mission to address unmet clinical needs, Novabio espouses core values of patient-centricity, integrity, pragmatism, and persistence, spearheading the industrialization of Treg development.
Established in 2013, OBiO Technology (stock code: 688238) is a leading biotechnology firm，stands at the forefront of gene and cell therapy, serving as a pioneering CRO and CDMO, dedicated to delivering comprehensive solutions. The state-of-the-art 77,000-square-meter Facility for Global Supply exemplifies our commitment to meeting worldwide demand. We excel in vectorology studies, functional genomics, and the development of processes and analytics, facilitating Investigational New Drug (IND) readiness and the full spectrum of clinical and commercial manufacturing. Guided by our mission to "enable gene therapy for better lives," we prioritize providing top-tier services on a global scale. From laboratory to clinic, we tirelessly advance your products, impacting populations across the globe. Our steadfast dedication ensures the delivery of high-quality CDMO services throughout the preclinical, IND, clinical, and commercial stages. Our offerings include expertise in plasmids, mRNA, AAV, LVV, Ad viral vectors, cell therapy, CAR-T, NK, Treg, oncolytic viruses, and cutting-edge technologies such as inducible viral vector packaging, ultralow endotoxin processes, and AAVneO for tissue-specific AAV variants.